Brian Simmons

3.0k total citations
34 papers, 402 citations indexed

About

Brian Simmons is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Brian Simmons has authored 34 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Brian Simmons's work include Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Brian Simmons is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Cancer Genomics and Diagnostics (10 papers) and Colorectal Cancer Treatments and Studies (8 papers). Brian Simmons collaborates with scholars based in United States, Australia and France. Brian Simmons's co-authors include Robert C. Doebele, Anna F. Farago, George D. Demetri, Stephen V. Liu, Diégo Tosi, John C. Krauss, Luis Paz‐Ares, George A. Stouffer, Thomas John and Edna Chow‐Maneval and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Brian Simmons

31 papers receiving 394 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Simmons United States	12	209	204	124	74	58	34	402
G. Tartarelli Italy	9	151 0.7×	136 0.7×	120 1.0×	82 1.1×	31 0.5×	18	444
D. Leitão Portugal	7	230 1.1×	180 0.9×	141 1.1×	86 1.2×	58 1.0×	10	525
Petros Giannikopoulos United States	8	157 0.8×	212 1.0×	213 1.7×	70 0.9×	25 0.4×	17	454
Chi-Chung Chan China	10	151 0.7×	126 0.6×	155 1.3×	61 0.8×	31 0.5×	24	414
Jason Porter United States	4	203 1.0×	82 0.4×	143 1.2×	46 0.6×	35 0.6×	6	359
Shaoqian Sun China	10	240 1.1×	132 0.6×	121 1.0×	108 1.5×	21 0.4×	14	453
Tatsuya Katayama Japan	8	132 0.6×	166 0.8×	191 1.5×	76 1.0×	46 0.8×	20	390
Takashi Sekikawa Japan	11	165 0.8×	144 0.7×	117 0.9×	46 0.6×	34 0.6×	33	408
Chiung-Kuei Huang United States	9	141 0.7×	129 0.6×	198 1.6×	148 2.0×	17 0.3×	9	404

Countries citing papers authored by Brian Simmons

Since Specialization

Citations

This map shows the geographic impact of Brian Simmons's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Simmons with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Simmons more than expected).

Fields of papers citing papers by Brian Simmons

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Simmons. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Simmons. The network helps show where Brian Simmons may publish in the future.

Co-authorship network of co-authors of Brian Simmons

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Simmons. A scholar is included among the top collaborators of Brian Simmons based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Simmons. Brian Simmons is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meneses‐Lorente, Georgina, Brian Simmons, Sarah E. McCallum, et al.. (2025). Clinical Exploration and Physiologically Based Modelling of the Impact of Hepatic Impairment on Entrectinib Pharmacokinetics. Clinical Pharmacokinetics. 64(3). 437–451.

Dziadziuszko, Rafał, Fabrice Barlési, Jeong Eun Kim, et al.. (2024). Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.. Journal of Clinical Oncology. 42(17_suppl). LBA2509–LBA2509.

Thomas, David M., Gennaro Daniele, Jeong Eun Kim, et al.. (2024). Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study.. Journal of Clinical Oncology. 42(16_suppl). 3092–3092. 2 indexed citations

Dziadziuszko, Rafał, Salvatore Siena, Daniel S.W. Tan, et al.. (2020). 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Annals of Oncology. 31. S833–S834. 5 indexed citations

Krebs, Matthew, Filippo de Braud, Salvatore Siena, et al.. (2020). 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis. Annals of Oncology. 31. S831–S833. 3 indexed citations

Ascierto, Paolo A., Karl D. Lewis, Anna Maria Di Giacomo, et al.. (2020). Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib. Annals of Oncology. 31(1). 153–159. 29 indexed citations

Liu, Stephen V., Filippo de Braud, Alexander Drilon, et al.. (2020). 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy. Annals of Oncology. 31. S472–S473. 1 indexed citations

Paz-Ares, L., Rafał Dziadziuszko, A. Drilon, et al.. (2019). MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases. Journal of Thoracic Oncology. 14(10). S305–S305. 5 indexed citations

Siena, Salvatore, George D. Demetri, Robert C. Doebele, et al.. (2019). Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Annals of Oncology. 30. iv134–iv134. 8 indexed citations

10.

Schadendorf, Dirk, Anna Maria Di Giacomo, Lev Demidov, et al.. (2019). Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib. European Journal of Cancer. 123. 155–161. 3 indexed citations

11.

Paz‐Ares, Luis, Robert C. Doebele, Anna F. Farago, et al.. (2019). Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 30. ii48–ii49. 23 indexed citations

12.

Doebele, Robert C., Luis Paz‐Ares, Anna F. Farago, et al.. (2019). Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Cancer Research. 79(13_Supplement). CT131–CT131. 11 indexed citations

13.

Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Annals of Oncology. 29. ix175–ix175. 30 indexed citations

14.

Demetri, George D., Luis Paz‐Ares, Anna F. Farago, et al.. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology. 29. viii713–viii713. 46 indexed citations

15.

Wang, Nan, Kimberly C. Vendrov, Brian Simmons, et al.. (2017). Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. Prostaglandins & Other Lipid Mediators. 134. 24–31. 19 indexed citations

16.

Abou‐Alfa, Ghassan K., Lionel D. Lewis, Patricia LoRusso, et al.. (2017). Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment. Cancer Chemotherapy and Pharmacology. 80(1). 29–36. 24 indexed citations

17.

Miles, David, S. B. Kim, Thierry Velu, et al.. (2016). First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study. Annals of Oncology. 27. vi89–vi89.

18.

Brufsky, Adam, Sung‐Bae Kim, Thierry Velu, et al.. (2016). Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. Journal of Clinical Oncology. 34(15_suppl). 1074–1074. 5 indexed citations

19.

Abou‐Alfa, Ghassan K., Lionel D. Lewis, Patricia LoRusso, et al.. (2015). Abstract CT308: Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic dysfunction. Cancer Research. 75(15_Supplement). CT308–CT308. 1 indexed citations

20.

Schuck, Robert N., Katherine N. Theken, Matthew L. Edin, et al.. (2013). Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis. 227(2). 442–448. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact